Nifty
Sensex
:
:
10767.40
36330.65
-73.25 (-0.68%)
-233.23 (-0.64%)

Pharmaceuticals & Drugs

Rating :
62/99  (View)

BSE: 500124 | NSE: DRREDDY

2727.70
-15.95 (-0.58%)
19-Sep-2019 | 9:59AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2740.10
  •  2748.20
  •  2720.00
  •  2743.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  72980
  •  1990.68
  •  2964.00
  •  1872.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 45,615.32
  • 21.21
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,230.62
  • 0.73%
  • 3.12

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.76%
  • 4.08%
  • 7.73%
  • FII
  • DII
  • Others
  • 0.23%
  • 13.48%
  • 47.72%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.26
  • 0.56
  • 2.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.35
  • -1.87
  • 5.15

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.42
  • -3.99
  • 14.88

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.06
  • 28.58
  • 32.69

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.62
  • 4.15
  • 3.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.70
  • 17.43
  • 16.67

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
3,858.20
3,736.50
3.26%
4,029.60
3,553.90
13.39%
3,864.60
3,834.10
0.80%
3,817.50
3,559.80
7.24%
Expenses
3,116.50
2,967.70
5.01%
3,210.70
2,990.30
7.37%
3,060.00
3,041.40
0.61%
3,058.20
2,890.40
5.81%
EBITDA
741.70
768.80
-3.52%
818.90
563.60
45.30%
804.60
792.70
1.50%
759.30
669.40
13.43%
EBIDTM
19.22%
20.58%
20.32%
15.86%
20.82%
20.68%
19.89%
18.80%
Other Income
430.10
50.40
753.37%
83.30
44.90
85.52%
102.30
43.00
137.91%
128.20
31.60
305.70%
Interest
29.80
19.50
52.82%
24.50
17.80
37.64%
24.10
17.20
40.12%
20.80
22.30
-6.73%
Depreciation
289.00
278.70
3.70%
287.20
276.30
3.94%
290.30
271.50
6.92%
278.60
270.20
3.11%
PBT
853.00
521.00
63.72%
590.50
314.40
87.82%
592.50
547.00
8.32%
588.10
408.50
43.97%
Tax
192.80
53.20
262.41%
150.80
49.20
206.50%
101.10
252.80
-60.01%
80.70
112.30
-28.14%
PAT
660.20
467.80
41.13%
439.70
265.20
65.80%
491.40
294.20
67.03%
507.40
296.20
71.30%
PATM
17.11%
12.52%
10.91%
7.46%
12.72%
7.67%
13.29%
8.32%
EPS
40.70
28.68
41.91%
27.43
16.39
67.36%
30.14
18.26
65.06%
31.22
18.42
69.49%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
15,569.90
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
Net Sales Growth
6.03%
8.17%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
 
Cost Of Goods Sold
4,696.80
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
Gross Profit
10,873.10
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
GP Margin
69.83%
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
Total Expenditure
12,445.40
12,270.00
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
Power & Fuel Cost
-
329.10
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
% Of Sales
-
2.13%
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
Employee Cost
-
3,356.20
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
% Of Sales
-
21.73%
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
Manufacturing Exp.
-
1,434.80
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
% Of Sales
-
9.29%
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
General & Admin Exp.
-
1,143.70
1,198.90
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
% Of Sales
-
7.40%
8.40%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
Selling & Distn. Exp.
-
1,423.50
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
% Of Sales
-
9.21%
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
Miscellaneous Exp.
-
87.90
70.50
70.60
483.00
65.70
35.60
38.50
85.20
147.00
691.00
% Of Sales
-
0.57%
0.49%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
EBITDA
3,124.50
3,178.20
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
EBITDA Margin
20.07%
20.57%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
Other Income
743.90
337.50
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
Interest
99.20
88.90
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
Depreciation
1,145.10
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
PBT
2,624.10
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
Tax
525.40
385.80
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
Tax Rate
20.02%
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
PAT
2,098.70
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
PAT before Minority Interest
2,098.70
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
13.48%
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
PAT Growth
58.58%
108.92%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
 
Unadjusted EPS
129.49
117.53
57.08
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
14,023.60
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
Share Capital
83.00
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
Total Reserves
13,861.10
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
Non-Current Liabilities
2,113.00
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
Secured Loans
55.20
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
Unsecured Loans
2,144.80
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
Long Term Provisions
79.30
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
Current Liabilities
5,897.30
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
Trade Payables
1,367.10
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
Other Current Liabilities
2,820.70
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
Short Term Borrowings
1,212.50
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
Short Term Provisions
497.00
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
Total Liabilities
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
Net Block
7,191.00
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
Gross Block
18,048.40
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
Accumulated Depreciation
10,845.80
10,463.00
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
Non Current Assets
10,923.80
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
Capital Work in Progress
2,933.50
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
Non Current Investment
334.20
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
Long Term Loans & Adv.
426.70
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
Other Non Current Assets
38.40
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
Current Assets
11,110.10
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
Current Investments
2,252.90
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
Inventories
3,357.90
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
Sundry Debtors
3,986.90
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
Cash & Bank
222.80
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
Other Current Assets
1,289.60
481.70
451.50
393.10
1,231.00
1,214.60
961.90
705.80
879.60
660.90
Short Term Loans & Adv.
439.80
958.30
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
Net Current Assets
5,212.80
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
Total Assets
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,870.40
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
PBT
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
Adjustment
1,639.60
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
Changes in Working Capital
-577.10
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
Cash after chg. in Working capital
3,354.50
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-484.10
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-772.70
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
Net Fixed Assets
-275.60
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
Net Investments
-297.00
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
Others
-200.10
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
Cash from Financing Activity
-2,132.60
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
Net Cash Inflow / Outflow
-34.90
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
Opening Cash & Equivalents
254.20
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
Closing Cash & Equivalent
222.80
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
840.01
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
ROA
8.66%
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
ROE
14.42%
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
ROCE
13.41%
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
Fixed Asset Turnover
0.87
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
Receivable days
94.98
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
Inventory Days
74.03
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
Payable days
39.46
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
Cash Conversion Cycle
129.55
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
Total Debt/Equity
0.28
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
Interest Cover
26.78
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06

News Update


  • Dr. Reddy's Lab launches Lansoprazole Delayed-Release Capsules in US market
    16th Sep 2019, 11:52 AM

    Dr. Reddy's OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, is an over-the-counter, PPI used to treat frequent heartburn occurring two or more days a week

    Read More
  • Dr. Reddy's Lab gets EIR from USFDA for manufacturing plants at Visakhapatnam
    13th Sep 2019, 09:49 AM

    The agency had conducted an audit of the company’s formulations manufacturing plants at Duvvada

    Read More
  • Dr. Reddy's Lab launches Bupropion Hydrochloride Extended-Release Tablets
    5th Sep 2019, 12:47 PM

    The Zyban brand and generic had US sales of approximately $5.4 million

    Read More
  • Dr Reddy's gets 8 observations from USFDA for its Duvvada facility
    21st Aug 2019, 09:56 AM

    The company has been issued Form 483 with 8 observations

    Read More
  • Dr. Reddy’s Lab launches Vigabatrin Powder for Oral Solution
    20th Aug 2019, 11:08 AM

    Vigabatrin Powder for Oral Solution, USP is available in 500 mg per packet in count size of 50 per carton

    Read More
  • Dr. Reddy’s Lab launches Versavo in India
    19th Aug 2019, 12:51 PM

    The company now has six biosimilar products commercialized in India

    Read More
  • Dr. Reddy’s Lab get CRL from USFDA for NuvaRing, Copaxone
    16th Aug 2019, 11:36 AM

    Copaxone is a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis

    Read More
  • USFDA completes audit at Dr. Reddy’s Laboratories’ Louisiana facility
    9th Aug 2019, 11:31 AM

    No Form 483 was issued at the end of the inspection

    Read More
  • Dr. Reddy's Laboratories’ arm enters into collaboration with Exelixis
    1st Aug 2019, 11:42 AM

    The agreement gives Exelixis the opportunity to in-license as many as six programs from Aurigene

    Read More
  • Dr. Reddy’s Laboratories launches Pregabalin Capsules in US Market
    30th Jul 2019, 14:49 PM

    Lyrica is a trademark of C.P. Pharmaceuticals International C.V

    Read More
  • Dr. Reddy's Lab gets nod to amalgamate DRHL with itself
    30th Jul 2019, 10:17 AM

    The Board of Directors of the Company at its meeting held on July 29, 2019 has approved the same

    Read More
  • Dr. Reddy's Laboratories reports 42% rise in Q1 consolidated net profit
    29th Jul 2019, 16:15 PM

    Total consolidated income of the company increased by 13.24% at Rs 4288.30 crore for Q1FY20

    Read More
  • Dr. Reddys Lab - Quarterly Results
    29th Jul 2019, 15:52 PM

    Read More
  • Dr Reddy's Laboratories launches Ramelteon Tablets in US Market
    23rd Jul 2019, 15:25 PM

    The company’s Ramelteon Tablets, are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000

    Read More
  • Dr. Reddy's Lab completes divestment of Zembrace Symtouch, Tosymra to Upsher-Smith
    20th Jul 2019, 14:37 PM

    The company has closed the transaction with Upsher-Smith, pursuant to the satisfactory completion of all customary closing conditions

    Read More
  • Dr Reddy's Lab launches Fexofenadine HCI, Pseudoephedrine HCI Extended-Release Tablets
    19th Jul 2019, 11:18 AM

    The company’s OTC Fexofenadine HCI 60 mg and Pseudoephedrine HCI 120 mg Extended-Release Tablets, USP are available in 20- and 30-count sizes

    Read More
  • USFDA completes audit at Dr. Reddy’s Laboratories’ Hyderabad plant
    12th Jul 2019, 14:40 PM

    The company has been issued a Form 483 with 5 observations

    Read More
  • Dr Reddy's Lab launches OTC store-brand equivalent of Mucinex D Extended Release Tablets
    9th Jul 2019, 11:41 AM

    The company’s OTC Guaifenesin 1200 mg and Pseudoephedrine HCI 120 mg is available in 24-count packages

    Read More
  • Dr Reddy's Laboratories planning to launch value-added drugs in US
    8th Jul 2019, 11:47 AM

    The company has also planning to re-focus some of its Research and Development resources

    Read More
  • Dr. Reddy's launches Carboprost Tromethamine Injection USP
    3rd Jul 2019, 12:54 PM

    Dr. Reddy's Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost

    Read More
  • Dr. Reddy's Lab launches Tobramycin Inhalation Solution in US market
    25th Jun 2019, 14:17 PM

    The company’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule

    Read More
  • USFDA completes audit at Dr. Reddy’s Laboratories’ Vizag Plants
    24th Jun 2019, 09:53 AM

    The company has been issued a Form 483 with 2 observations

    Read More
  • Dr. Reddy's Lab launches Phytonadione Injectable Emulsion in US
    24th Jun 2019, 09:00 AM

    The Vitamin K1 for Injectable Emulsion USP, 10 mg/ml brand and generic had combined US sales of approximately $46.6 million MAT

    Read More
  • Dr. Reddy's Lab enters into definitive agreement with Upsher-Smith Laboratories, LLC
    14th Jun 2019, 09:39 AM

    Under the agreement, the company will receive $70 million as upfront consideration, $40.5 million in near term milestones

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.